Late onset neonatal sepsis (LOS) has a high mortality and the optimal management is
poorly defined. We aimed to evaluate new expert panel-derived criteria to define LOS and …

Background The early use of broad-spectrum antibiotics remains the cornerstone for the
treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still …

Background Late-Onset Neonatal Sepsis (LOS) is a rare condition, involving widespread
infection, immune disruption, organ dysfunction, and often death. Because exposure to …

Background Late onset neonatal sepsis (LOS) with the mortality of 17 to 27% is still a serious
disease. Meropenem is an antibiotic with wide antibacterial coverage. The advantage of it …

Late-Onset Neonatal Sepsis (LOS) is a rare, but life-threatening condition, involving widespread
infection, immune disruption, organ dysfunction, and often death. Because exposure to …

Background Meropenem is used for treatment of late onset sepsis (LOS) but is not licensed
in neonates. We aimed to compare the efficacy and safety of meropenem to standard of care (…

Dysregulation of T cell apoptosis contributes to the pathogenesis of acute systemic
inflammation–induced immunosuppression, as seen in sepsis and trauma. However, the regulatory …

Background Glyco-lipopeptides, a form of lipid-tailed glyco-peptide, are currently under intense
investigation as B- and T-cell based vaccine immunotherapy for many cancers. However, …

Purpose Late-onset sepsis (LOS) is a clinical condition that results in serious morbidity and
mortality in preterm neonates. The aim of this study was to identify differences in clinical and …

Background: Glyco-lipopeptides, a form of lipid-tailed glyco-peptide, are currently under intense
investigation as B-and T-cell based vaccine immunotherapy for many cancers. However, …